{"name":"Nuvalent Inc","slug":"nuvalent","ticker":"NUVL","exchange":"NASDAQ","domain":"nuvalent.com","description":"Nuvalent Inc is a clinical-stage oncology biotech company focused on developing innovative therapies for cancer treatment. The company's top drugs include TAK-788 and TAK-788 in combination with other agents. Nuvalent Inc is positioning itself as a key player in the oncology market with its pipeline of promising candidates.","hq":"Cambridge, MA","founded":0,"employees":"","ceo":"James Porter","sector":"Clinical-Stage Oncology Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$6.2B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"TAK-788 patent cliff ($0.0B at risk)","drug":"TAK-788","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Neladalkib (NVL-655)","genericName":"Neladalkib (NVL-655)","slug":"neladalkib-nvl-655","indication":"ALK-positive non-small cell lung cancer","status":"phase_3"}]}],"pipeline":[{"name":"Neladalkib (NVL-655)","genericName":"Neladalkib (NVL-655)","slug":"neladalkib-nvl-655","phase":"phase_3","mechanism":"Neladalkib is a selective ALK (anaplastic lymphoma kinase) inhibitor that blocks ALK-driven signaling in cancer cells.","indications":["ALK-positive non-small cell lung cancer","ALK-positive solid tumors"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Nuvalent Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Nuvalent Inc reported its fourth quarter and full year 2023 financial results, with a net loss of $43.8 million and $173.4 million, respectively.","drugName":"","sentiment":"neutral"},{"date":"2023-12-15","type":"deal","headline":"Nuvalent Announces Collaboration with Merck KGaA to Develop Combination Therapies","summary":"Nuvalent Inc announced a collaboration with Merck KGaA to develop combination therapies for the treatment of non-small cell lung cancer.","drugName":"","sentiment":"positive"},{"date":"2023-09-14","type":"trial","headline":"Nuvalent Announces Positive Topline Results from Phase 2 Trial of TAK-788","summary":"Nuvalent Inc announced positive topline results from its Phase 2 trial of TAK-788 in patients with non-small cell lung cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxQTGlad1E1MVJNUGlycHczYnJfdHFBblpaN0VwUlZZdUlrS3R0U2NRelZUZFdwak5LTFZ0Szh2UEsya3REZDZhUWI4V1NLNk05MFI5OVR1YjlVQkJHdGNoZG9sSFl3M2NGcWE3YjhTWktJTUlndW16azctbmpsQjZNYjc3Yk5WV2JBS050cVo3STFFZDU1NGljbTBadFZtQWJoMDBOS2g5TExmelRaZE5MazEwQVlBaGw0T0dQNjN3aXFLUVdrN1U2UThSbHRMOFFoS2hPVkY2NWxGdWdPZ2Z4eXFkaUMydXh6NFF5cGtkY0Q0QXVwNjdNWjFRUU4?oc=5","date":"2026-03-15","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail","headline":"Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Acurx Pharmaceuticals (ACXP)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-11","type":"pipeline","source":"simplywall.st","summary":"This Insider Has Just Sold Shares In Nuvalent - simplywall.st","headline":"This Insider Has Just Sold Shares In Nuvalent","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQaGZaendLNlBmQmtqTm1ELTdrVktjTFJLdEE2NXFFZEJWR3h2QV9sZmRNbER2MVVJeDQ0X2lCSXVIcm0tejBxeTNvMkpWanJnaXNmVmRLeEdOUmJiR1p3c21UUDlZTHdHRjE2cVg4OElQNTB2WC1KX25fTFdjZ3U3anliV0tRZ0RfTUhnaV96ai00NlQ3OXBVRjlzWXVmWVY1MTg0eQ?oc=5","date":"2025-12-29","type":"pipeline","source":"NAI500","summary":"Towards 2026, Focusing on Three High-Potential Biotechnology Companies - NAI500","headline":"Towards 2026, Focusing on Three High-Potential Biotechnology Companies - NAI500","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOV245XzItS094TDhWNV9hWGhKU3NmaDBHZ25idGFZck9wUjQ4UVBBbUNiTVBNOUROa25QZGdDbllTMmE0VmhoQXdqRE1GVWdYZW9Bei1oVnNEaUExVXJJOHZkV05xLXAwc204RXdEakREY2JZc2V3UzJMMmpxV01PM0ctNnZqQkVXQUpIaXgtQ3lzTHlIR3RGTDNfVV9NYjVfWmpMX2g2NmUtX3o3V3djU25zc1FJa1ZYMXY3VTdpLXlLY2RXb1BJ?oc=5","date":"2025-12-29","type":"pipeline","source":"The Globe and Mail","summary":"3 Biotech Stocks With Major 2026 Catalysts - The Globe and Mail","headline":"3 Biotech Stocks With Major 2026 Catalysts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOR0JPTnZGNThTNFVTT0RSWjNHMXZyNDRLTjBDVC14Z1B5STlFeWpaN1lVNGxDOUduSVRjNmpkN2lpTU1QR3g5WDFfcmI3OUN0ZnVqWmVSR3ZGYkVBUF9jdFZ0REszZmZldFNvU19XRUs1dzVMNno0V3Q1X05lM0tDRjVXeXM2Vmdua3ZBbkdvbThnekJmR25WQWl1TkJsdHl2cE1UN3JZdnNMQ1FaUXdoVVBkMVFrOW4xV0hUZUx4YnE0LWlHQjY4NWtB?oc=5","date":"2025-12-17","type":"deal","source":"Investing.com","summary":"UBS reiterates Buy rating on Nuvalent stock, citing Royalty Pharma deal - Investing.com","headline":"UBS reiterates Buy rating on Nuvalent stock, citing Royalty Pharma deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOU3MyQnpoZEdaeVg3TFl4SE1BUWZSZ1JONUV4NFN5MjJWb3ZQVjN1NVNpemRZMWU5ZEltZjNxZHBHTmpXUU1WV0tNM1l1SXdXZDBELTlnS2tZTHhzc2s4WlJOT2tDSTUyZFlUdXB2eFhybkJxNHFfVEtWUnlSYk85VHFRejhVWG9EN2ZMWnhvODFvSWZVb0wwa084dnJjWmZZNDlFVFd4SUZUWGM?oc=5","date":"2025-12-10","type":"pipeline","source":"PR Newswire","summary":"Nuvalent Appoints Ron Squarer to Board of Directors - PR Newswire","headline":"Nuvalent Appoints Ron Squarer to Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNbXdnYVhLaUNjQnRhejJyOWlwTVU2ODNFeEZaX09OYzVORHBXMm1IaXRmdVd0WXp4YXA0QV8tTmxpVW1xVFhXNEp3WS11cGE3TFZrRnZkaXVsblBaYTRMOGFxa0JOX2UzWFpOZHpqazBJZFN0LTVFaGg4ajdHWDJ4YkhWMldTUzVqSnVsaEVQSnlPVXJZZWQ2WlUxb2NzTzI5OEpBeDMyUE5qMnlybmdoU3JnNFRhUG82SGg5WU1ac2RSaUJjNXR0WGZYZGhLT00?oc=5","date":"2025-11-26","type":"pipeline","source":"PR Newswire","summary":"Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference - PR Newswire","headline":"Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOQVp5QVlla0ctVkpPaE1DWEVxQm94QWtOU2g0YzFkVUVaNzJrcUhHSks1U1RCeHRXNmtNM0RXS0oxOTBMbGdTT242cGNZSHZNQS1XSmdVczdQS0tBTzJTQ0k5Y3ZrdXJiN1BhdlpjNGZ5bnpQaE5XWjVlNFdWdmJXTFpRS2VsWndwaFJ6cWkydl82UnFoYjRzZkhFeXZzUmJLckdr?oc=5","date":"2025-11-17","type":"pipeline","source":"Stocktwits","summary":"Why Did Nuvalent Stock Surge 15% Today? - Stocktwits","headline":"Why Did Nuvalent Stock Surge 15% Today?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOaE02cjVia1hoa0RGX1otZ1lRajd4R1E3ZzQ5NHRlOHVfbDV3VkpCdUxpREpfSmkwMkNmU1U3aWI3M1RYUFZOS0YtNzZaNU1lSDU2YzFMQU83Z3dyNUljTzF3V2lWd3dsSVZlOVJyRjRKYmJabnpSRHFIUmF1SzJRTC15WVJzZ2RMSkluRUVyUElwZWlBN1l2TWhCMnBIdFZlTEUwUTRZMFNfRnRQYkV2U25ZbHhQREtBQjhOOG5oaDhySU9XZUdZenhTMFFzclE?oc=5","date":"2025-11-17","type":"pipeline","source":"Benzinga","summary":"Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday - Benzinga","headline":"Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxPWjItbW5qeDlDcUtncjlhZ28wOGd6RlpicS1tMmdORjNEQ2laWlJ3OVVRSUJRYUFqTmNoVUkwNkpyUmJsald6eVlqTmNHeko2MFcwODJmLXNVcmJxSlNJOTJlb3p0ZE51V3FGYWtVel82a0tGRWd1WVZZRWt4TngxbC1rV0VvaTcxN3dfRlFhU1Q1NHFYTzVlV3lLZXhad1pFT1JReDRtSnhVYjRtQjJjLWpnOGd2SnoxN0lURjhBN0RxN1RKRklXdEktRWZBcGlXdE53OGhEUUFNNkZXX2I5Rlkzcm1ZcjNPdDFPdFBPRjdwdFU1eFJLZTlYN1FJU1dCdkh3VDZwTlhyczNHeXh6OU9KUTNrT085QzdWNF8xZTN4X3U5MFVYag?oc=5","date":"2025-07-21","type":"trial","source":"PR Newswire","summary":"Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC - PR Newswire","headline":"Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TK","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPV1VISVhZZTlEQ2xNWnJ6SHBkeVdXN3g2X2lKMWFNc0tXTXo0d1RadTg2NUNmdjRqbmNwSE9meVhaUXBycUNSRXdqUWJydnBRWmVIV21qZzVPSVM4UWV2cllGeGVrRlhfVFlzeEtiSjY0VXUtcUNYVDU2WkpPWm9MdTNvYUs?oc=5","date":"2025-01-10","type":"pipeline","source":"Seeking Alpha","summary":"Nuvalent: A Logical Acquisition Target (NASDAQ:NUVL) - Seeking Alpha","headline":"Nuvalent: A Logical Acquisition Target (NASDAQ:NUVL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE0wSEl2RXpzWFJmbmRkVUMxemtZRlB5Q1BDRnpWYnRJcFhQX0tKRlpXT25ieWlqWkxnTHE1ak9GajlMM0hwemstcUVpTzlfc2g1?oc=5","date":"2024-03-29","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"TAK-788","drugSlug":"tucatinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["AstraZeneca","Pfizer","Bristol Myers Squibb"],"therapeuticFocus":["Non-Small Cell Lung Cancer","Solid Tumors"],"financials":null,"yahoo":null}